{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:28:33Z","timestamp":1793910513286,"version":"4.8.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,11,5]],"date-time":"2027-11-05T00:00:00Z","timestamp":1825372800000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104840","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:20:42Z","timestamp":1792772442000},"page":"104840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methadone: Historical success, modern challenges and lessons for opioid drug discovery"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-7713","authenticated-orcid":false,"given":"Ennian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4169-6590","authenticated-orcid":false,"given":"Preet","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-7016","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104840_b0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0963689718811060","article-title":"Historical review: opiate addiction and opioid receptors","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Transplant"},{"key":"10.1016\/j.drudis.2026.104840_b0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1049909107312597","article-title":"Methadone","volume":"25","author":"Chhabra","year":"2008","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.drudis.2026.104840_b0015","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40263-020-00743-3","article-title":"Methadone for pain management: a pharmacotherapeutic review","volume":"34","author":"Kreutzwiser","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2026.104840_b0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like \u2018liquid handcuffs\u2019\u201d: the effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.drudis.2026.104840_b0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.drudis.2026.104840_b0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cpt1977212147","article-title":"Clinical effects and pharmacokinetics of racemic methadone and its optical isomers","volume":"21","author":"Olsen","year":"1977","journal-title":"Clin Pharma Therapeutics"},{"key":"10.1016\/j.drudis.2026.104840_b0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1749-6632.1948.tb27252.x","article-title":"Pharmacology of methadone and related compounds","volume":"51","author":"Chen","year":"1948","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.drudis.2026.104840_b0040","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A Medical treatment for diacetylmorphine (Heroin) addiction: a clinical trial with methadone hydrochloride","volume":"193","author":"Dole","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2026.104840_b0045","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1001\/jama.1968.03150120042009","article-title":"Successful treatment of 750 criminal addicts","volume":"206","author":"Dole","year":"1968","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2026.104840_b0050","series-title":"Federal Regulation of Methadone Treatment","year":"1995"},{"key":"10.1016\/j.drudis.2026.104840_b0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jps.10263","article-title":"Determination of l-alpha-acetylmethadol (LAAM), norLAAM, and dinorLAAM in clinical and in vitro samples using liquid chromatography with electrospray ionization and tandem mass spectrometry","volume":"92","author":"Huang","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2026.104840_b0060","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1021\/jm00203a014","article-title":"Synthesis and analgesic activity of some long-acting piperidinospiro derivatives of methadone","volume":"21","author":"Frincke","year":"1978","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104840_b0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hup.630","article-title":"The effects of methadone and its role in fatalities","volume":"19","author":"Corkery","year":"2004","journal-title":"Human Psychopharmacol"},{"key":"10.1016\/j.drudis.2026.104840_b0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on problems of drug dependence clinical practice guideline","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"},{"key":"10.1016\/j.drudis.2026.104840_b0075","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/jclp.23582","article-title":"Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder","volume":"79","author":"Wang","year":"2023","journal-title":"J Clin Psychol"},{"key":"10.1016\/j.drudis.2026.104840_b0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/s-0044-1787571","article-title":"Opioid maintenance therapy: a review of methadone, buprenorphine, and naltrexone treatments for opioid use disorder","volume":"44","author":"Fipps","year":"2024","journal-title":"Semin Neurol"},{"key":"10.1016\/j.drudis.2026.104840_b0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jlac.19495610107","article-title":"\u00dcber eine neue Klasse von spasmolytisch und analgetisch wirkenden Verbindungen","volume":"561","author":"Bockm\u00fchl","year":"1949","journal-title":"I Justus Liebigs Ann Chem"},{"key":"10.1016\/j.drudis.2026.104840_b0090","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/ja01204a006","article-title":"A new synthesis and confirmation of the structure of amidone1","volume":"69","author":"Easton","year":"1947","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104840_b0095","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1039\/jr9500001478","article-title":"306. Synthetic analgesics. Part IX. Synthesis of compounds related to amidone","volume":"153","author":"Morrison","year":"1950","journal-title":"J Chem Soc"},{"key":"10.1016\/j.drudis.2026.104840_b0100","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1021\/acs.jmedchem.4c02605","article-title":"New synthesis and pharmacological evaluation of enantiomerically pure (R)- and (S)-methadone metabolites as N-methyl-d-aspartate receptor antagonists","volume":"68","author":"Banzato","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104840_b0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.2042-7158.1995.tb05786.x","article-title":"Phenyl-substituted normethadones: synthesis and pharmacology","volume":"47","author":"Mbela","year":"1995","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.drudis.2026.104840_b0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-3565(25)05180-8","article-title":"Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines","volume":"107","author":"Eddy","year":"1953","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104840_b0115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/jm00348a016","article-title":"Conformation-activity study of methadone and related compounds","volume":"25","author":"Froimowitz","year":"1982","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104840_b0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jlac.19697280111","article-title":"\u00fcber Cyclohexene, I Synthese und Reaktionen von 4\u2010Phenyl\u20103\u2010amino\u2010cyclohexenen\u2010(1), einer neuen Klasse von Analgetica","volume":"728","author":"Satzinger","year":"1969","journal-title":"Justus Liebigs Ann Chem"},{"key":"10.1016\/j.drudis.2026.104840_b0125","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1021\/jm00348a015","article-title":"Synthesis, x-ray crystallographic determination, and opioid activity of erythro-5-methylmethadone enantiomers. Evidence which suggests that.mu. and.delta. opioid receptors possess different stereochemical requirements","volume":"25","author":"Portoghese","year":"1982","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104840_b0130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1039\/JR9490000500","article-title":"113. Analgesics. Part I. Esters and ketones derived from \u03b1-amino-\u03c9-cyano-\u03c9\u03c9 diarylalkanes","volume":"152","author":"Dupr\u00e8","year":"1949","journal-title":"J Chem Soc"},{"key":"10.1016\/j.drudis.2026.104840_b0135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.2042-7158.1957.tb12290.x","article-title":"A new series of potent analgesics","volume":"9","author":"Janssen","year":"1957","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.drudis.2026.104840_b0140","unstructured":"Eddy NB. Synthetic substances with morphine-like effect. Published online. 1958."},{"key":"10.1016\/j.drudis.2026.104840_b0145","series-title":"Opiates","author":"Lenz","year":"1986"},{"key":"10.1016\/j.drudis.2026.104840_b0150","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1021\/jm00229a001","article-title":"Quantum chemical studies of methadone","volume":"19","author":"Loew","year":"1976","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104840_b0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid \u00b5 receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104840_b0160","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41380-023-02353-z","article-title":"Unique pharmacodynamic properties and low abuse liability of the \u00b5-opioid receptor ligand (S)-methadone","volume":"29","author":"Levinstein","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.drudis.2026.104840_b0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/mol.119.119339","article-title":"Atomic-level characterization of the methadone-stabilized active conformation of \u00b5-opioid receptor","volume":"98","author":"Kapoor","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104840_b0170","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41386-019-0501-x","article-title":"N-methyl-d-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects","volume":"44","author":"Foga\u00e7a","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2026.104840_b0175","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(94)00937-6","article-title":"The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine","volume":"56","author":"Kristensen","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2026.104840_b0180","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn3504","article-title":"NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease","volume":"14","author":"Paoletti","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.drudis.2026.104840_b0185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14737175.2019.1643237","article-title":"An update on NMDA antagonists in depression","volume":"19","author":"Pochwat","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.drudis.2026.104840_b0190","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)38234-5","article-title":"d-methadone blocks morphine tolerance and N-methyl-d-aspartate-induced hyperalgesia1","volume":"289","author":"Davis","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104840_b0195","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/s41380-024-02621-6","article-title":"Letter to the Editor regarding \u2018Unique pharmacodynamic properties and low abuse liability of the \u00b5-opioid receptor ligand (S)-methadone\u2019","volume":"29","author":"Pappagallo","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.drudis.2026.104840_b0200","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bph.14105","article-title":"Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome","volume":"175","author":"Rickli","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104840_b0205","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916654146","article-title":"Characterization of methadone as a \u03b2-arrestin-biased \u03bc-opioid receptor agonist","volume":"12","author":"Doi","year":"2016","journal-title":"Mol Pain"},{"key":"10.1016\/j.drudis.2026.104840_b0210","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/tpj.2010.37","article-title":"\u03b2-Arrestin2 influences the response to methadone in opioid-dependent patients","volume":"11","author":"Oneda","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.drudis.2026.104840_b0215","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/pan.12385","article-title":"The pharmacokinetics of methadone and its metabolites in neonates, infants, and children","volume":"24","author":"Ward","year":"2014","journal-title":"Pediatr Anesth"},{"key":"10.1016\/j.drudis.2026.104840_b0220","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.4103\/IJPC.IJPC_180_17","article-title":"Practical pharmacology of methadone: a long-acting opioid","volume":"24","author":"Sunilkumar","year":"2018","journal-title":"Indian J Palliat Care"},{"key":"10.1016\/j.drudis.2026.104840_b0225","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2026.104840_b0230","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1556-4029.12627","article-title":"Distribution of enantiomers of methadone and its main metabolite EDDP in human tissues and blood of postmortem cases","volume":"60","author":"Holm","year":"2015","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.drudis.2026.104840_b0235","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF00194951","article-title":"Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts","volume":"48","author":"De Vos","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104840_b0240","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2026.104840_b0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N\u2010demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"10.1016\/j.drudis.2026.104840_b0250","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104840_b0255","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/bcpt.13975","article-title":"Methadone pharmacokinetics in opioid agonist treatment: influencing factors and clinical implications","volume":"134","author":"Chalabianloo","year":"2024","journal-title":"Basic Clin Pharma Tox"},{"key":"10.1016\/j.drudis.2026.104840_b0260","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0022-3565(24)29338-1","article-title":"Blockade of Rat alpha3\u03b24 nicotinic receptor function by methadone, its metabolites, and structural analogs","volume":"299","author":"Xiao","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104840_b0265","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","article-title":"Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"},{"key":"10.1016\/j.drudis.2026.104840_b0270","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/cpt.3338","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2B6 genotype and methadone therapy","volume":"116","author":"Robinson","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104840_b0275","first-page":"1353","article-title":"Methadone treatment for pain states","volume":"71","author":"Toombs","year":"2005","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.drudis.2026.104840_b0280","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104840_b0285","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0957-4166(03)00019-3","article-title":"Synthesis of optically active methadones, LAAM and bufuralol by lipase-catalysed acylations","volume":"14","author":"Hull","year":"2003","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.drudis.2026.104840_b0290","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0740-5472(97)00176-1","article-title":"Levo-alpha acetyl methadol (LAAM) its advantages and drawbacks","volume":"14","author":"Finn","year":"1997","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.drudis.2026.104840_b0295","unstructured":"Orlaam (levomethadyl acetate): side effects, uses, dosage, interactions, warnings. Accessed 26 June 2026."},{"key":"10.1016\/j.drudis.2026.104840_b0300","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.102.038240","article-title":"Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents","volume":"303","author":"Katchman","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104840_b0305","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1300\/J069v20n04_02","article-title":"Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM)","volume":"20","author":"Deamer","year":"2001","journal-title":"J Addict Dis"},{"key":"10.1016\/j.drudis.2026.104840_b0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2047-783X-14-1-7","article-title":"Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation \u2013 results from a controlled clinical trial","volume":"14","author":"Wieneke","year":"2009","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.drudis.2026.104840_b0315","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1360-0443.2007.01976.x","article-title":"Can LAAM, like Lazarus, come back from the dead?","volume":"102","author":"Jaffe","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drudis.2026.104840_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126042","article-title":"Novel oral LAAM immediate-release capsules for treating opioid use disorder","volume":"683","author":"Zhen","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104840_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123041","article-title":"Janus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder","volume":"317","author":"Sudarjat","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2026.104840_b0330","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2024.06.071","article-title":"Nor-LAAM loaded PLGA microparticles for treating opioid use disorder","volume":"373","author":"Ingabire","year":"2024","journal-title":"J Controlled Release"},{"key":"10.1016\/j.drudis.2026.104840_b0335","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into \u00b5-opioid receptor activation","volume":"524","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104840_b0340","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","article-title":"Structure of the \u00b5-opioid receptor\u2013Gi protein complex","volume":"558","author":"Koehl","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104840_b0345","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.tips.2020.09.009","article-title":"Critical assessment of G protein-biased agonism at the \u03bc-opioid receptor","volume":"41","author":"Gillis","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104840_b0350","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104840_b0355","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrd1032","article-title":"ADMET in silico modelling: towards prediction paradise?","volume":"2","author":"Van de Waterbeemd","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104840_b0360","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104840_b0365","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104840_b0370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3483","article-title":"A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates","volume":"10","author":"Ding","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104840_b0375","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/ALN.0000000000001529","article-title":"Respiratory effects of the nociceptin\/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers","volume":"126","author":"Dahan","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2026.104840_b0380","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.2174\/1568026620666200508082615","article-title":"Nociceptin\/orphanin FQ peptide receptor-related ligands as novel analgesics","volume":"20","author":"Kiguchi","year":"2020","journal-title":"CTMC"},{"key":"10.1016\/j.drudis.2026.104840_b0385","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-023-01878-5","article-title":"Nociceptin receptor-related agonists as safe and non-addictive analgesics","volume":"83","author":"Ding","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104840_b0390","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrd.2017.232","article-title":"Automating drug discovery","volume":"17","author":"Schneider","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104840_b0395","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"Sliwoski","year":"2014","journal-title":"Pharmacol Rev"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600245X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600245X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:45:09Z","timestamp":1793907909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462600245X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S135964462600245X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104840","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methadone: Historical success, modern challenges and lessons for opioid drug discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104840"}}